Risk of Bleeding After Percutaneous Endoscopic Gastrostomy in Patients Using Antithrombotic Drugs.

Autor:	Parlar YE; Department of Gastroenterology, Hacettepe University, Ankara, Turkey., Mustafayev F; Department of Gastroenterology, Aegean Hospital, Baku, Azerbaijan., Vahabov C; Department of Gastroenterology, Aegean Hospital, Baku, Azerbaijan., Şahin T; Department of Gastroenterology, Hacettepe University, Ankara, Turkey., İsrafilov S; Department of Gastroenterology, Hacettepe University, Ankara, Turkey., Keskin O; Department of Gastroenterology, Hacettepe University, Ankara, Turkey., Balaban HY; Department of Gastroenterology, Hacettepe University, Ankara, Turkey., Kav T; Department of Gastroenterology, Hacettepe University, Ankara, Turkey., Parlak E; Department of Gastroenterology, Hacettepe University, Ankara, Turkey., Şimşek H; Department of Gastroenterology, Hacettepe University, Ankara, Turkey., Sivri B; Department of Gastroenterology, Hacettepe University, Ankara, Turkey.
Jazyk:	angličtina
Zdroj:	Surgical laparoscopy, endoscopy & percutaneous techniques [Surg Laparosc Endosc Percutan Tech] 2023 Oct 01; Vol. 33 (5), pp. 540-542. Date of Electronic Publication: 2023 Oct 01.
DOI:	10.1097/SLE.0000000000001210
Abstrakt:	Background: The rate of using antithrombotic (AT) drugs is frequently high in patients who require percutaneous endoscopic gastrostomy (PEG). The aim of this study was to determine whether the risk of bleeding after PEG increases in patients whose AT drugs were discontinued according to the European Society Gastrointestinal Endoscopy guidelines (warfarin for 5 d, low molecular weight heparin for 24 h, DOAC for 3 d, and clopidogrel for 7 d). Patients and Methods: Data from 243 patients, who underwent PEG tube placement and received AT drugs and 206 patients who did not between 2018 and 2021 in our hospital, were evaluated retrospectively. Bleeding was defined as requiring blood transfusion, hematemesis and/or melena, decreased hemoglobin, or bleeding from PEG. Results: A total of 243 (54.1%) patients (121 (49.7%), women, mean age (75.7 y) who underwent PEG and received AT drugs, and 206 (45.9%) patients who did not (92 (44.6%), women, mean age (63.15 y). The medications and bleeding rates of the patients are given in Table 1. The rate of bleeding in patients using AT medication was significantly higher than that in patients not using medication (Table 2) ( P = 0.007). When the AT drugs were compared among themselves, the bleeding risk did not differ. Bleeding was detected in 10 patients with bleeding from the PEG tube in 4 with melena. Bleeding detected in 14 patients was controlled with adrenaline injections. None of the patients required transfusion or repeat endoscopies. No bleeding-related deaths were reported. Conclusion: Even if patients receiving AT drugs are treated as recommended by international guidelines, it should be kept in mind that bleeding may occur after PEG, and the patients should be followed accordingly. Competing Interests: The authors declare no conflicts of interest. (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu